Current Drug Therapy

Dual antiplatelet therapy for acute coronary syndromes: How long to continue?

Meghana Halkar, MD and A. Michael Lincoff, MD
Cleveland Clinic Journal of Medicine September 2016, 83 (9) 675-688; DOI: https://doi.org/10.3949/ccjm.83a.15092

ABSTRACT

For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.

Footnotes

  • Dr. Lincoff has disclosed research support from AstraZeneca, CSL Behring, Edwards LifeSciences, Eli Lilly, Esperion, Medtronic, Pfizer, Regado, Roche, and Takeda and consulting and membership on advisory committees or review panels for Roche.

View Full Text
  1. Meghana Halkar, MD⇑
  1. Department of Cardiovascular Medicine, MedStar Washington Hospital Center, Washington, DC
  1. ADDRESS:
    Meghana Halkar, MD, FACP, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, 106 Irving Street, Washing-ton, DC 20010; meghanahalkar{at}gmail.com
  1. A. Michael Lincoff, MD
  1. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic
  2. Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

ABSTRACT

For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.

Footnotes

  • Dr. Lincoff has disclosed research support from AstraZeneca, CSL Behring, Edwards LifeSciences, Eli Lilly, Esperion, Medtronic, Pfizer, Regado, Roche, and Takeda and consulting and membership on advisory committees or review panels for Roche.

View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects